Related Experiment Video
Updated: Aug 16, 2026
Preterm EEG: A Multimodal Neurophysiological Protocol
Published on: February 18, 2012
Antenatal hormone therapy for improving the outcome of the preterm infant
1University of Pennsylvania School of Medicine, Philadelphia, USA.
Insights
Antenatal glucocorticoid therapy significantly improves lung development in preterm infants, reducing respiratory distress and mortality. This treatment also decreases other serious complications, enhancing infant survival and well-being.
Area of Science:
- Neonatal Medicine
- Pulmonology
- Pharmacology
Background:
- Antenatal therapy with glucocorticoids has been studied since 1972 for improving preterm infant outcomes.
- Physiologic stress levels of corticosteroids accelerate lung maturation via receptor-mediated protein induction.
- Multiple trials confirm benefits, including reduced respiratory distress syndrome (RDS) and mortality.
Purpose of the Study:
- To review the established benefits of antenatal glucocorticoid therapy in preterm infants.
- To highlight the impact on pulmonary outcomes and other neonatal morbidities.
- To discuss current recommendations and future therapeutic possibilities.
Main Methods:
- Review of historical data and multiple controlled trials on antenatal glucocorticoid therapy.
- Analysis of outcomes including respiratory distress syndrome, mortality, intraventricular hemorrhage, and necrotizing enterocolitis.
- Consideration of National Institutes of Health Consensus Conference recommendations.
Main Results:
- Antenatal glucocorticoids decrease respiratory distress syndrome and mortality in preterm infants.
- Therapy is associated with reduced intraventricular hemorrhage, patent ductus arteriosus, and necrotizing enterocolitis.
- Proven benefits support widespread use in pregnancies between 24-34 weeks gestation.
Conclusions:
- Antenatal glucocorticoid therapy is a cornerstone in managing preterm birth, significantly improving pulmonary and overall neonatal outcomes.
- Current recommendations support its use for fetuses between 24-34 weeks gestation.
- Combination therapy with thyrotropin-releasing hormone shows potential for further reducing RDS and chronic lung disease.
Abstract:
The value of antenatal therapy with glucocorticoids in improving the pulmonary outcome of preterm human infants was first demonstrated in 1972. Accelerated lung maturation occurs with physiologic stress levels of corticosteroid by receptor-mediated induction of specific developmentally regulated proteins. Since the first report by Liggins, multiple controlled trials have demonstrated a decreased number of cases of respiratory distress syndrome and mortality in treated infants. In addition, prenatal therapy leads to decreased intraventricular hemorrhage and hospital costs, and there is strong evidence for decreased incidence of both patent ductus arteriosus requiring therapy and necrotizing enterocolitis. The recommendations of the 1994 National Institutes of Health Consensus Conference include use of antenatal corticosteroids in virtually all women who are in labor when the fetus is between 24 to 34 weeks' gestation. The combination of antenatal corticosteroids with thyrotropin releasing hormone holds promise for further reducing the incidence and severity of respiratory distress syndrome and decreasing chronic lung disease in the preterm infant.
More Related Videos
07:36Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
11:50Clinical Practice Protocol of Creative Music Therapy for Preterm Infants and Their Parents in the Neonatal Intensive Care Unit
Published on: January 7, 2020
Related Concept Videos
01:07Teratogenicity
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...